breaking

Biocon Eyes Generic GLP-1 Market as Novo Nordisk Slashes India Prices

Biocon is moving aggressively into generic glucagon-like peptide-1 medications as competition intensifies in India's weight-loss and diabetes drug market. The push comes after Novo Nordisk cut prices sharply on its branded treatments, triggering a 40% surge in sales following the price reductions despite an influx of generic alternatives. Biocon Chief Executive Shreehas Tambe outlined the company's strategy to capture market share in the rapidly expanding segment. The price reductions have accelerated demand for GLP-1 therapies across India, where obesity and diabetes cases continue rising. Generic manufacturers are capitalizing on lower price points to reach cost-conscious patients. The competitive landscape is reshaping India's pharmaceutical sector, with established players like Biocon seeking to balance branded and generic offerings.